THERANOSTICS 2016* Harshad Kulkarni
Zentralklinik Bad Berka, THURINGIA, Germany
- This delegate is presenting an abstract at this event.
Presentations this author is a contributor to:
Efficacy of peptide receptor radionuclide therapy in neuroendocrine neoplasms: the Bad Berka experience in 1048 patients over more than a decade (#64)
8:30 AM
Harshad R Kulkarni
Conference Breakfast: Moderated Poster Walk - Neuroendocrine tumours
Prostate specific membrane antigen targeted radioligand therapy of metastatic castration-resistant prostate cancer using Lu-177 PSMA-617: safety, efficacy and dosimetry in comparison with Lu-177 PSMA I&T (#33)
4:06 PM
Harshad R Kulkarni
Improving Patient Outcomes with PSMA Theranostics
Establishing a routine method for the manual labeling of PSMA-I&T and PSMA-617 with Lutetium-177 under GMP conditions (#98)
8:30 AM
Harshad R Kulkarni
Conference Breakfast: Moderated Poster Walk - Prostate tumours